The estimated Net Worth of James M Demesa is at least $5.88 mil dollars as of 7 November 2018. James Demesa owns over 8,500 units of OncoSec Medical Inc stock worth over $5,880 and over the last 12 years he sold ONCS stock worth over $0. In addition, he makes $0 as Independent Director at OncoSec Medical Inc.
Sign up
James DeMesa ONCS stock SEC Form 4 insiders trading
James has made over 1 trades of the OncoSec Medical Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 8,500 units of ONCS stock worth $6,970 on 7 November 2018.
The largest trade he's ever made was buying 8,500 units of OncoSec Medical Inc stock on 7 November 2018 worth over $6,970. On average, James trades about 607 units every 0 days since 2013. As of 7 November 2018 he still owns at least 21,001 units of OncoSec Medical Inc stock.
You can see the complete history of James Demesa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James DeMesa biography
Dr. James Michael DeMesa M.D. serves as Independent Director of the Company. Dr. DeMesa has been a practicing physician and has served as a senior executive with several international pharmaceutical and biotech companies, both public and private, in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. In addition to OncoSec, Dr. DeMesa is currently on the Boards of Directors of Induce Biologics, a regenerative medicine company, and Integene International, a gene-therapy company. In August 2008, Dr. DeMesa retired from his role as President, Chief Executive Officer and a director of Migenix Inc., a public biotechnology company focused on infectious and neurodegenerative diseases. From 1997 to 2001, he was President, Chief Executive Officer and a director of GenSci Regeneration Sciences Inc., a public biotech company involved in regenerative medicine (now part of Integra LifeSciences, NASD: IART). During his tenure at these two companies, Dr. DeMesa led the acquisition of several technologies and companies and completed multiple strategic partnership transactions with companies such as J&J, Astellas Pharmaceuticals, and Cadence Pharmaceuticals. He also led multiple successful financings totaling over $150 million. From 1992 to 1997, he was Vice President, Medical and Regulatory Affairs at Biodynamics International, Inc. (now part of RTI Surgical, NASD: RTIX), and from 1989 to 1992 was Vice President, Medical and Regulatory Affairs of Bentley Pharmaceuticals (now part of Teva Pharmaceuticals). Dr. DeMesa is a co-founder of CommGeniX, a medical communications company, and MedXcel, a medical education company. Dr. DeMesa attended the University of South Florida where he received his B.A. (Chemistry), M.D., and M.B.A. degrees and did his medical residency at the University of North Carolina. He is the author of two books and speaks regularly to companies and organizations throughout North America.
How old is James DeMesa?
James DeMesa is 62, he's been the Independent Director of OncoSec Medical Inc since 2011. There are 1 older and 9 younger executives at OncoSec Medical Inc. The oldest executive at OncoSec Medical Inc is Margaret Dalesandro, 73, who is the Independent Chairman of the Board.
What's James DeMesa's mailing address?
James's mailing address filed with the SEC is 24, North Main Street, Pennington, Mercer County, New Jersey, 08534, United States of America.
Insiders trading at OncoSec Medical Inc
Over the last 12 years, insiders at OncoSec Medical Inc have traded over $1,474,366 worth of OncoSec Medical Inc stock and bought 9,275,650 units worth $39,853,210 . The most active insiders traders include Grand Pharmaceutical & Heal..., Holdings, Inc. Alpha y Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of $51,563. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth $55.
What does OncoSec Medical Inc do?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
What does OncoSec Medical Inc's logo look like?
Complete history of James Demesa stock trades at OncoSec Medical Inc
OncoSec Medical Inc executives and stock owners
OncoSec Medical Inc executives and other stock owners filed with the SEC include:
-
Daniel O'Connor,
President, Chief Executive Officer, Director -
Robert J. DelAversano CPA,
VP of Fin. and Principal Accounting Officer & Controller -
Margaret Dalesandro,
Independent Chairman of the Board -
Herbert Lyerly,
Independent Director -
Chao Zhou,
Director -
Yuhang Zhao,
Director -
Kevin Smith,
Director -
Robert DelAversano,
Principal Accounting Officer, Controller -
Robert Ward,
Independent Director -
James DeMesa,
Independent Director -
Joon Kim,
Director -
Dr. Mai Hope Le M.D.,
Consultant -
Dr. Sandra Aung Ph.D.,
Sr. VP & Chief Clinical Devel. Officer -
Tu Diep M.Sc.,
Sr. VP & Head of Operations -
Dr. Kim Jaffe,
Assistant VP of Bus. Devel. & Operations -
Robert Hamilton Pierce,
Chief Medical Officer -
Sheela Mohan Peterson,
Chief Legal Officer -
Sharron E Gargosky,
Chief Clinical & Reg. Officer -
Anthony E Iii Maida,
Director -
Mai Hope Le,
Chief Medical Officer -
Richard B Slansky,
Chief Financial Officer -
Avtar S Dhillon,
Director -
Punit Dhillon,
President and CEO -
Annalisa Jenkins,
Director -
Gregory T. Mayes,,
Director -
Sara Bonstein,
CFO/COO -
Spahr Stephany Foster,
Director -
Veronica Vallejo,
Chief Financial Officer -
Grand Pharmaceutical & Heal...,
-
Kellie Malloy Foerter,
Chief Operating Officer -
Holdings, Inc. Alpha,
Director -
Brian A Leuthner,
Interim CEO -
Robert H. Arch,
President and CEO